Abbott Laboratories (ABT) Tops Q1 EPS by 5c; Reaffirms FY14 Outlook
Tweet
Share
E-mailGet Alerts ABT Hot Sheet
Price: $108.33 -0.42%
Revenue Growth %: +14.2%
Financial Fact:
Other (income) expense, net: 972M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +14.2%
Financial Fact:
Other (income) expense, net: 972M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Abbott Laboratories (NYSE: ABT) reported Q1 ongoing EPS of $0.41, $0.05 better than the analyst estimate of $0.36. Revenue for the quarter came in at $5.24 billion versus the consensus estimate of $5.29 billion.
Abbott reaffirmed FY2014 guidance.
For earnings history and earnings-related data on Abbott Laboratories (ABT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- Goldman Sachs Downgrades Schindler Holding AG (SCHN:SW) (SHLAF) to Sell
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
